Journal article
Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors
Current hypertension reports, Vol.25(11), pp.395-404
11/2023
DOI: 10.1007/s11906-023-01265-1
Abstract
Purpose of Review
Use of renin–angiotensin–aldosterone system (RAAS) inhibiting medications is critical in the prevention of cardiovascular disease and kidney function decline in patients with chronic kidney disease (CKD); however, these agents can lead to hyperkalemia, an electrolyte disorder associated with risk of arrythmia, conduction disorders, and increased overall mortality. Discontinuation, or reduction of dose, of RAAS inhibitor therapy in hyperkalemic patients with CKD can lead to loss of kidney and cardiovascular protection afforded by these medications. Given the high prevalence of hyperkalemia among patients with CKD utilizing RAAS inhibitors, clear management principles are critical to minimize risk and maximize benefit when facing this clinical dilemma.
Recent Findings
Strategies to mitigate hyperkalemia that do not interfere with optimal RAAS inhibitor therapy should be prioritized when managing potassium elevation in patients with CKD. These strategies include discontinuing non-RAAS inhibitor medications known to cause hyperkalemia, correction of metabolic acidosis, and maximization of medication therapies that lower serum potassium, including diuretics and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Initiation of potassium exchange resins should also be considered to allow for sustained RAAS inhibitor utilization. An approach which employs multiple strategies concurrently is important to mitigate hyperkalemia and maintain long-term use of RAAS-inhibitors.
Summary
Persistence of RAAS inhibitor use in patients with CKD is important to slow kidney function decline, delay onset of dialysis or the need for kidney transplant, and prevent adverse cardiovascular outcomes. When hyperkalemia develops among patients with CKD utilizing a RAAS inhibitor, a deliberate effort to reduce serum potassium levels using an approach that allows for continuation of maximally dosed RAAS inhibitor therapy is important. Patient education and engagement in the potassium management process is important for sustained success.
Details
- Title: Subtitle
- Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors
- Creators
- Michelle A. Fravel - University of IowaCalvin J. Meaney - University at Buffalo, State University of New YorkLama Noureddine - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Current hypertension reports, Vol.25(11), pp.395-404
- DOI
- 10.1007/s11906-023-01265-1
- ISSN
- 1522-6417
- eISSN
- 1534-3111
- Language
- English
- Electronic publication date
- 09/25/2023
- Date published
- 11/2023
- Academic Unit
- Nephrology; Pharmacy Practice and Science; Internal Medicine
- Record Identifier
- 9984472535502771
Metrics
1 Record Views